K. Stott

Inhibitors of Amyloid Aggregation: Technologies for the Discovery of Novel Lead Compounds

A. Doig, J. Mark Treherne, K. Stott, 2004, Biotechnology & genetic engineering reviews.

Design strategies for anti-amyloid agents.

A. Doig, J. Mason, K. Stott, 2003, Current opinion in structural biology.

N-Methylated peptide inhibitors of beta-amyloid aggregation and toxicity. Optimization of the inhibitor structure.

A. Doig, J. Mason, K. Stott, 2006, Biochemistry.

Improving the assessment of the probability of success in late stage drug development

Björn Holzhauer, Lisa V. Hampson, Björn Bornkamp, 2021, Pharmaceutical statistics.

Incorporation of glutamine repeats makes protein oligomerize: implications for neurodegenerative diseases.

M. Perutz, P. Butler, J. Blackburn, 1995, Proceedings of the National Academy of Sciences of the United States of America.

Crystal structure of a dimeric chymotrypsin inhibitor 2 mutant containing an inserted glutamine repeat.

M. Perutz, Y. W. Chen, K. Stott, 1999, Proceedings of the National Academy of Sciences of the United States of America.

N-methylated peptide inhibitors of β-amyloid aggregation and toxicity

A. Doig, D. Scopes, J. Mark Treherne, 2007 .

Solution studies of chymotrypsin inhibitor-2 glutamine insertion mutants show no interglutamine interactions.

D. Neuhaus, D. Gordon-Smith, R. J. Carbajo, 2001, Biochemical and biophysical research communications.